Nov 08, 2018 09:43 JST

Source: Eisai

Eisai Commences Full-Scale Operation of New Suzhou Plant in China
Strengthens In-House Domestic Production System in China

TOKYO, Nov 08, 2018 - (JCN Newswire) - Eisai Co., Ltd. announced today that its Chinese subsidiary, Eisai China Inc. (ECI) has commenced full-scale operation of its new Suzhou plant located within the Suzhou Industrial Park, and an opening ceremony was held accordingly.

(from left: Kazuyuki Katayama, Consulate-General of Japan in Shanghai; Wu Qingwen, Deputy Mayor, Suzhou Municipality, SIPAC Secretary General of the Party Committee; Haruo Naito, Eisai Co., Ltd. CEO; Wang Yue, Jiangsu Food and Drug Administration Head of Bureau)
 


http://www.acnnewswire.com/topimg/Low_EisaiNewSuzhou%20.jpg
(from left: Kazuyuki Katayama, Consulate-General of Japan in Shanghai; Wu Qingwen, Deputy Mayor, Suzhou Municipality, SIPAC Secretary General of the Party Committee; Haruo Naito, Eisai Co., Ltd. CEO; Wang Yue, Jiangsu Food and Drug Administration Head of Bureau)

Aiming to further expand its contribution to patients in China, Eisai has been working to establish the new Suzhou plant as the plant with the largest production capacity under the Eisai Group on a new industrial site more than five times larger than the former Suzhou plant (oral solid dose production facility scheduled for closure at the end of November 2018) at approximately 134,000m2 in size to further strengthen the stable supply chain as well as improve production efficiency. The new Suzhou plant's oral solid dose production facility has a production capacity (formulation of approximately 3 billion tablets / packaging for approximately 5 billion tablets per year) which is approximately double that of the former Suzhou plant, and handles the formulation and packaging of oral solid dose products such as Methycobal, Aricept and Pariet for the domestic Chinese market. In addition, ECI established a parenteral facility (production capacity: 60 million bottles per year) in advance in November 2014, where it manufactures the injection formulation of Methycobal.

Eisai's business operations in China are one of its core businesses which is third-largest in scale after Japan and the United States. With the full-scale commencement of operations at the new Suzhou plant, Eisai seeks to strengthen its in-house domestic production system in China and expand its stable supply chain of high quality pharmaceuticals, contributing to increasing the benefits to patients and their families in China.

Contact:
Public Relations Department,
Eisai Co., Ltd.
+81-3-3817-5120
Source: Eisai
Sectors: BioTech

Copyright ©2024 JCN Newswire. All rights reserved. A division of Japan Corporate News Network.

Related Press Release


Eisai: Research on Treatments for Alzheimer's Disease Based on Its Pathological Mechanisms Recieves Award for Science and Technology (Research Category)
April 18 2024 09:53 JST
 
Eisai's Antiepileptic Drug Fycompa Injection Formulation Launched In Japan
April 17 2024 15:17 JST
 
French Sales Subsidiary Eisai S.A.S. to Divest Rights for Loxapac And Parkinane LP to CNX Therapeutics
April 03 2024 15:24 JST
 
Eisai Completes Submission of LEQEMBI (lecanemab-irmb) Supplemental Biologics License Application for IV Maintenance Dosing for the Treatment of Early Alzheimer's Disease to the U.S. FDA
April 01 2024 08:39 JST
 
Eisai to Divest Rights for Merislon and Myonal in Japan to Kaken Pharmaceutical
March 29 2024 14:51 JST
 
Eisai's Brain Health Self-Check Tool "NouKNOW" is Certified as "ME-BYO BRAND" by Kanagawa Prefecture
March 29 2024 14:19 JST
 
Eisai: Discovery Research on Dual Orexin Receptor Antagonist Lemborexant Honored with PSJ Award for Drug Research and Development 2024
March 29 2024 13:32 JST
 
Lifenet and Eisai Co-Develop Dementia Insurance "be"
March 21 2024 16:36 JST
 
Eisai Selected as a Nadeshiko Brand 2024 as a Listed Company Excelling in Promotion of Women in the Workplace
March 21 2024 15:10 JST
 
Eisai Invests in C2N to Support Simplifying the Diagnosis of Early Alzheimer's Disease to Better Serve Patients
March 06 2024 16:47 JST
 
More Press release >>

Latest Press Release


More Latest Release >>